
    
      B1991002 study is a phase 1 adaptive design study which terminated on 14Mar2011. Regular
      analyzes of psoriasis assessments conducted per the statistical plan indicate that even if
      every patient enrolled for the rest of the study respond (up to 23 additional subjects), the
      study can not meet its primary efficacy endpoint. Pfizer Inc. has terminated the trial and
      clinical team is asking all clinical investigators to continue collecting safety,
      pharmacokinetics and pharmacodynamics data until the last subject last visit for all subjects
      who received test article. Last Subject Last Visit occurred 20May2011.
    
  